Fda Issues Warning for Patients On Erbitux
Deseret News (Salt Lake City) › September 15, 2005
Linked as:
Summary
WASHINGTON (AP) -- The government is warning doctors to monitor patients who take Erbitux, a drug for colorectal cancer, for an hour after they receive an injection because of occasional reactions that include trouble breathing, hives or dangerously low blood pressure.
The Food and Drug Administration, along with manufacturers ImClone and Bristol-Myers Squibb, on Wednesday announced changes to the drug's warning label that includes the monitoring advice.See the full content of this document
Extract
Fda Issues Warning for Patients On Erbitux
The warning s...
See the full content of this document
Sponsored links
